Midday movers: Adobe, Zillow fall; Micron rises

Go back to Midday movers: Adobe, Zillow fall; Micron rises

Madrigal Pharmaceuticals (MDGL) PT Raised to $405 at Evercore ISI, 'well positioned to execute on the launch of Rezdiffra'

March 19, 2024 2:50 PM UTC

Evercore ISI analyst Liisa Bayko raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $405.00 (from $325.00) while maintaining a Outperform rating.

The analyst comments "With clean label in hand & an additional $600M in the bank, Madrigal is well positioned to execute on the... More

Micron Technology (MU) PT Raised to $110 at CFRA

March 19, 2024 1:37 PM UTC

CFRA analyst Angelo Zino raised the price target on Micron Technology (NASDAQ: MU) to $110.00 (from $94.00) while maintaining a Buy rating.

The analyst comments "We boost our 12-month target to $110 from $94, on a P/E of 12.6x our CY 25 EPS view, near MU's long-term... More

Stifel on Micron Technology (MU) Ahead of Earnings Tomorrow: 'Regaining profitability just an intermediate stepping stone'

March 19, 2024 6:09 AM UTC

Stifel analyst Brian Chin reiterated a Buy rating and $120.00 price target on Micron Technology (NASDAQ: MU).

The analyst comments "Micron reports F2Q(Feb) earnings this Wednesday (after the close). We expect the company to report a narrower loss en route to... More

Micron Technology (MU) PT Raised to $115 at Baird, 'DRAM Supply/Demand Could Return to Equilibrium by C4Q'

March 19, 2024 5:06 AM UTC

Baird analyst Tristan Gerra raised the price target on Micron Technology (NASDAQ: MU) to $115.00 (from $78.00) while maintaining a Neutral rating.

The analyst comments "Raising our estimates and price target on strong pricing momentum. DRAM sufficiency should reach a trough in June and... More

Citi Closes 30-Day Upside Catalyst Watch on Madrigal Pharmaceuticals (MDGL)

March 18, 2024 4:04 PM UTC

Citi analyst David Lebowitz reiterated a Buy rating and $389.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst comments "We are closing our Catalyst Watch for Madrigal following the approval of Rezdiffra (resmetirom) for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH, also known as metabolic... More

Rosenblatt on Micron Technology (MU): 'We expect Micron to deliver a beat and raise', 'remains our top cyclical pick'

March 18, 2024 7:02 AM UTC

Rosenblatt analyst Hans Mosesmann reiterated a Buy rating and $140.00 price target on Micron Technology (NASDAQ: MU).

The analyst comments "We expect Micron to deliver a beat and raise on Wednesday, March 20th, on continued AI-driven segment demand, a bottoming in the broader markets (recovery... More

Micron Technology (MU) PT Raised to $120 at Cantor Fitzgerald

March 18, 2024 6:35 AM UTC

Cantor Fitzgerald analyst C.J. Muse raised the price target on Micron Technology (NASDAQ: MU) to $120.00 (from $100.00) while maintaining a Overweight rating.

The analyst comments "We look for a solid beat and raise from Micron this earnings report. The good news: look for mgmt to continue to signal expectations for Supply/ Demand trends to continue to tighten... More

Telsey Downgrades Hibbett Sports (HIBB) to Market Perform, 'Guidance Reflects Tougher Than Expected 2024'

March 18, 2024 5:04 AM UTC

Telsey analyst Cristina Fernandez downgraded Hibbett Sports (NASDAQ: HIBB) from Outperform to Market Perform with a price target of $74.00 (from $82.00).

The analyst comments "We are downgrading our rating on HIBB to Market Perform from Outperform given that 2024 is projected to be a more difficult year than we anticipated... More

Hibbett Sports (HIBB) PT Raised to $70 at B.Riley

March 15, 2024 12:14 PM UTC

B.Riley analyst Anna Glaessgen raised the price target on Hibbett Sports (NASDAQ: HIBB) to $70.00 (from $60.00) while maintaining a Neutral rating.

The analyst comments "Hibbett, Inc. (HIBBNeutral, $70 PT) 4Q comps and margins came in below the Street but essentially in line with... More